Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $3.0 million.

  • Orchestra BioMed Holdings' Share-based Compensation rose 2745.35% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year increase of 4052.36%. This contributed to the annual value of $10.6 million for FY2024, which is 3921.31% up from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Share-based Compensation stood at $3.0 million for Q3 2025, which was up 2745.35% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Share-based Compensation registered a high of $3.5 million during Q3 2023, and its lowest value of $70000.0 during Q1 2022.
  • Moreover, its 4-year median value for Share-based Compensation was $2.4 million (2024), whereas its average is $2.1 million.
  • As far as peak fluctuations go, Orchestra BioMed Holdings' Share-based Compensation surged by 202714.29% in 2023, and later tumbled by 3264.96% in 2024.
  • Orchestra BioMed Holdings' Share-based Compensation (Quarter) stood at $863000.0 in 2022, then increased by 6.49% to $919000.0 in 2023, then skyrocketed by 215.78% to $2.9 million in 2024, then rose by 3.82% to $3.0 million in 2025.
  • Its Share-based Compensation stands at $3.0 million for Q3 2025, versus $3.2 million for Q2 2025 and $3.0 million for Q1 2025.